China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
SAN DIEGO, Feb. 11, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Thursday, February 25, 2016 | |||
| Time: | 4:30 p.m. ET | |||
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |||
| Confirmation code: | 49757304 | |||
| Live webcast: | www.retrophin.com in the "Events & Presentations" section of the "Investors" page | |||
A replay of the call will be available 7:30 p.m. ET, February 25, 2016 to 11:59 p.m. ET, March 3, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 49757304.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the company’s marketed products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
